A view of hashish clones at Harborside Oakland Dispensary on August 11, 2025 in Oakland, California.
Justin Sullivan | Getty Photos
The Trump administration moved Thursday to reclassify hashish underneath federal regulation, which may considerably increase scientific analysis into the drug’s medical makes use of.
The change wouldn’t legalize the drug on the federal stage, however shift hashish from its present standing as a Schedule I substance to Schedule III underneath the U.S. Drug Enforcement Administration’s managed substances framework.
Medication in Schedule I, which embody heroin and LSD, are thought of to haven’t any accepted medical use and a excessive potential for abuse. Schedule III medication, like Tylenol with codeine and testosterone, against this are acknowledged as having medical functions and are topic to fewer regulatory restrictions.
Reclassification lowers longstanding limitations which have made it troublesome for researchers to review hashish in medical settings.
The monetary implications are important too. It exempts hashish corporations from IRS Code Part 280E, permitting them to deduct customary bills like lease and payroll for the primary time, and opens the door for banking entry that was beforehand barred.
The transfer marks some of the important federal shifts on marijuana coverage in a long time, signaling a rising willingness in Washington to rethink how the drug is categorized and studied within the U.S.
Scientists have confronted strict approval processes, restricted provide entry and heavy compliance necessities when making an attempt to look at hashish for therapeutic use, together with persistent ache, PTSD and neurological issues. These federal limitations remained in place at the same time as roughly half of states have legalized marijuana for leisure use, and much more have authorized it for medical use.
“Whereas operators would nonetheless face a fragmented state-by-state system, the improved money movement from rescheduling would assist reinvestment, strengthen stability, and assist construct momentum for extra constant requirements over time,” mentioned Wendy Bronfein, co-founder and chief model officer at Curio Wellness, a Maryland-based hashish firm.
The motion follows an government order issued final yr directing federal businesses to start the reclassification course of, which generally unfolds over a number of years and includes scientific assessment, interagency coordination and rulemaking procedures.
“This rescheduling just isn’t the end line — it’s the ultimate stage of a race we now have been operating for many years,” mentioned Shawn Hauser, accomplice at hashish regulation agency Vicente LLP.
In 2024, the Biden administration began that course of and put reclassification earlier than the general public for a 60-day remark interval. After that window, hearings to assessment potential hurdles stalled within the handoff between administrations.
The transfer additionally comes simply days after President Donald Trump signed an government order on psychedelics to speed up analysis, medical trials and “Proper to Attempt” entry for medication like psilocybin, MDMA and ibogaine.
